Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 25, 2015 6:07 PM ET

Healthcare Providers and Services

Company Overview of 23andMe, Inc.

Company Overview

23andMe, Inc. operates as a personal genetics company that provides ancestry-related genetic reports and uninterpreted raw genetic data. The company helps individuals understand their own genetic information through DNA analysis technologies and Web-based interactive tools. Its Personal Genome Service enables individuals to gain deeper insights into their ancestry and inherited traits. The company was founded in 2006 and is based in Mountain View, California.

1390 Shorebird Way

Mountain View, CA 94043

United States

Founded in 2006





Key Executives for 23andMe, Inc.

Co-Founder, Chief Executive Officer and Director
President and Director
Age: 48
Chief Financial Officer and Head of Operations
Age: 52
Chief Science Officer and Head of Therapeutics
Age: 62
Chief Medical Officer
Compensation as of Fiscal Year 2015.

23andMe, Inc. Key Developments

23andMe Won't Consider IPO In 2016

23andMe, Inc. raised $115 million in venture-capital financing. Andy Page, President of 23andMe, Inc. said, "The proceeds will be sufficient for the near term, meaning that 23andMe won’t consider an initial public offering in 2016."

23andMe, Inc. Appoints Dean Schorno as Chief Financial Officer and Head of Operations

23andMe, Inc. announced the appointment of Dean Schorno, CPA, as chief financial officer and head of operations for the company. In his new role, Schorno will oversee 23andMe's global financial and clinical laboratory operations. Schorno brings a wealth of experience to the job, most recently, serving as chief financial officer of Adaptive Biotechnologies. Before that he held executive leadership positions at Genomic Health. As CFO at Adaptive Biotechnologies, Schorno lead all financial operations which included a significant financing and acquisition for the company. He was also responsible for laboratory operations and facilities management.

23andMe, Inc. Presents at UBS Genomics 2.0 Summit, Aug-13-2015 09:15 AM

23andMe, Inc. Presents at UBS Genomics 2.0 Summit, Aug-13-2015 09:15 AM. Venue: The St. Regis Deer Valley, Park City, Utah, United States. Speakers: Andrew W. Page, President and Director.

Similar Private Companies By Industry

Company Name Region
Bettendorf Nursing Home Company, LLC United States
UPMC Lee Regional United States
South Jersey Emergency Physicians, PA United States
Cedar Ridge Treatment Center LLC United States
Abilities in Motion, Inc. United States

Recent Private Companies Transactions

Private Placement
June 18, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact 23andMe, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at